Ivan S Grozdev1, Abby S Van Voorhees2, Alice B Gottlieb3, Sylvia Hsu4, Mark G Lebwohl5, Bruce F Bebo6, Neil J Korman7. 1. Department of Dermatology and Murdough Family Center for Psoriasis, University Hospitals Case Medical Center, Cleveland, Ohio. 2. Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania. 3. Department of Dermatology, Tufts Medical Center, Boston, Massachusetts. 4. Department of Dermatology, Baylor College of Medicine, Houston, Texas. 5. Department of Dermatology, Mount Sinai School of Medicine, New York, New York. 6. National Psoriasis Foundation, Portland, Oregon. 7. Department of Dermatology and Murdough Family Center for Psoriasis, University Hospitals Case Medical Center, Cleveland, Ohio. Electronic address: njk2@case.edu.
Abstract
BACKGROUND: The continuous increase in the US population older than 65 years and the chronic course of psoriasis make management of psoriasis in the elderly an important health care problem. OBJECTIVE: We sought to develop a treatment algorithm for patients with psoriasis who are older than 65 years. METHODS: A systematic literature search for studies on elderly patients with psoriasis was performed using MEDLINE. RESULTS: We summarize the available published data on therapeutic modalities used in the elderly. We suggest a treatment algorithm including topical medications as first-line treatment for limited disease, with phototherapy, systemic retinoids, methotrexate, and biologics as the first-line systemic treatments for patients with more extensive disease. Cyclosporine should only rarely be used as a second-line systemic treatment for extensive disease in elderly patients with psoriasis. LIMITATIONS: Limited data are available regarding treatment modalities specifically for elderly patients with psoriasis. CONCLUSION: Appropriate treatment for elderly patients with limited psoriasis includes topical corticosteroids, topical vitamin D analogues, and topical tazarotene. For appropriately monitored elderly patients who have psoriasis with extensive disease, phototherapy, acitretin, methotrexate, alefacept, etanercept, adalimumab, infliximab, and ustekinumab are first-line therapies that can generally be safely used. There remains a need for further research on the management of psoriasis in elderly patients with psoriasis.
BACKGROUND: The continuous increase in the US population older than 65 years and the chronic course of psoriasis make management of psoriasis in the elderly an important health care problem. OBJECTIVE: We sought to develop a treatment algorithm for patients with psoriasis who are older than 65 years. METHODS: A systematic literature search for studies on elderly patients with psoriasis was performed using MEDLINE. RESULTS: We summarize the available published data on therapeutic modalities used in the elderly. We suggest a treatment algorithm including topical medications as first-line treatment for limited disease, with phototherapy, systemic retinoids, methotrexate, and biologics as the first-line systemic treatments for patients with more extensive disease. Cyclosporine should only rarely be used as a second-line systemic treatment for extensive disease in elderly patients with psoriasis. LIMITATIONS: Limited data are available regarding treatment modalities specifically for elderly patients with psoriasis. CONCLUSION: Appropriate treatment for elderly patients with limited psoriasis includes topical corticosteroids, topical vitamin D analogues, and topical tazarotene. For appropriately monitored elderly patients who have psoriasis with extensive disease, phototherapy, acitretin, methotrexate, alefacept, etanercept, adalimumab, infliximab, and ustekinumab are first-line therapies that can generally be safely used. There remains a need for further research on the management of psoriasis in elderly patients with psoriasis.
Authors: Jalpa A Doshi; Junko Takeshita; Lionel Pinto; Penxiang Li; Xinyan Yu; Preethi Rao; Hema N Viswanathan; Joel M Gelfand Journal: J Am Acad Dermatol Date: 2016-03-04 Impact factor: 11.527
Authors: Marieke E C van Winden; Elke L M ter Haar; Hans M M Groenewoud; Peter C M van de Kerkhof; Elke M G J de Jong; Satish F K Lubeek Journal: Acta Derm Venereol Date: 2020-07-28 Impact factor: 3.875
Authors: E L M Ter Haar; S E Thomas; J M P A van den Reek; M E Otero; M D Njoo; P M Ossenkoppele; E N Kop; S R P Dodemont; J E M Körver; A L A Kuijpers; R J Lindhout; R A Tupker; J M Mommers; M A M Berends; M I A Koetsier; M S de Bruin-Weller; M B Visch; W P Arnold; P P M van Lümig; M M Kleinpenning; S F K Lubeek; E M G J de Jong Journal: Drugs Aging Date: 2022-07-21 Impact factor: 4.271